


L1 HAS NO ANSWERS
L1 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 9 3
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> s l1 ful
FULL SEARCH INITIATED 08:31:57 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 17390 TO ITERATE


100.0% PROCESSED 17390 ITERATIONS
SEARCH TIME: 00.00.01

100 ANSWERS

L3 100 SEA SSS FUL L1

AN 2003:818416 CAPLUS
 DN 139:323436
 TI Preparation of pyridinoylpiperidines as 5-HT_{1F} agonists
 IN Cohen, Michael Philip; Kohlman, Daniel Timothy; Liang, Sidney Xi; Mancuso, Vincent; Victor, Frantz; Xu, Yao-Chang; Ying, Bai-Ping; Zacherl, Deanna Piatt; Zhang, Deyi
 PA Eli Lilly and Company, USA
 SO PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084949	A1	20031016	WO 2003-US8455	20030327
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	TW 263497	B	20061011	TW 2003-92106334	20030321
	NZ 534952	A	20051125	NZ 2003-534952	20030324
	CA 2478229	A1	20031016	CA 2003-2478229	20030327
	AU 2003224719	A1	20031020	AU 2003-224719	20030327
	EP 1492786	A1	20050105	EP 2003-721402	20030327
	EP 1492786	B1	20061004		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	BR 2003008495	A	20050201	BR 2003-8495	20030327
	CN 1642939	A	20050720	CN 2003-807363	20030327
	JP 2005530722	T	20051013	JP 2003-582146	20030327
	AT 341543	T	20061015	AT 2003-721402	20030327
	ZA 2004007666	A	20060222	ZA 2004-7666	20040922
	US 2005222206	A1	20051006	US 2004-509770	20040928
	NO 2004004654	A	20041028	NO 2004-4654	20041028
	HK 1073464	A1	20070504	HK 2005-104936	20050613
PRAI	US 2002-369088P	P	20020329		
	WO 2003-US8455	W	20030327		
OS	CASREACT 139:323436; MARPAT 139:323436				
GI					




AB Title compds. [I; R₁ = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, Ph, heterocycle; R₂ = H, alkyl, cycloalkylalkyl, pyrazolylalkyl; R₃ = H, alkyl; R₄ = H, halo, alkyl; R₅ = H, alkyl], were prepared for activating 5-HT_{1F} receptors, inhibiting neuronal protein extravasation, and for the

treatment or prevention of migraine. Thus, 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (preparation given), 4-fluorobenzoyl chloride, and Et₃N were stirred in CH₂Cl₂ at room temperature for 4 h to give 4-fluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)pyridin-2-yl]benzamide dihydrochloride. I bound to as 5-HT_{1F} receptors with K_i <300 nM. I drug formulations are given.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d scan 121


L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 5-bromo-2-methoxy-N-[6-[(1-methyl-4-piperidiny)carbonyl]-2-pyridiny]- (9CI)
MF C20 H22 Br N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):15

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 4-fluoro-N-[6-[(1-methyl-4-piperidiny)carbonyl]-2-pyridiny]-2-(trifluoromethyl)-, monohydrochloride (9CI)
MF C20 H19 F4 N3 O2 : Cl H




● HCl

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 7-Benzofurancarboxylic acid, 2,3-dihydro-
MF C9 H8 O3




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Propanal
MF C3 H6 O
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzamide, 2-methoxy-6-methyl-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
MF C21 H25 N3 O3



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 1H-Indole-3-carboxamide, N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)

MF C21 H22 N4 O2
CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Benzoic acid, 2-methoxy-4-(methylthio)-
MF C9 H10 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN 3-Furancarboxylic acid
MF C5 H4 O3
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN Benzamide, 2,6-difluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
 MF C19 H19 F2 N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, N-ethyl-2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
 MF C21 H22 F3 N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzoic acid, 2-[(4,6-dimethoxy-2-pyrimidinyl)oxy]- (9CI)
 MF C13 H12 N2 O5
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 1,4-Benzenedicarboxylic acid, 1-methyl ester
 MF C9 H8 O4
 CI COM




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Benzamide, 2-fluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]-4-(trifluoromethyl)- (9CI)
 MF C20 H19 F4 N3 O2




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L21 155 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 3-Furancarboxamide, N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI)
 MF C17 H19 N3 O3



=> d 14
 L4 HAS NO ANSWERS
 L4 STR



NODE ATTRIBUTES:
 DEFAULT MLEVEL IS ATOM
 DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
 RSPEC 9 3
 NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> search 14
 ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:l3
 'L3' IS NOT A VALID SEARCH SCOPE
 ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset
 ENTER SUBSET L# OR (END):l3
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 08:32:27 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 12 TO ITERATE

100.0% PROCESSED 12 ITERATIONS 11 ANSWERS
 SEARCH TIME: 00.00.01

L5 11 SEA SUB=L3 SSS FUL L4

=> s l5

L6 2 L5

=> d bib abs 1-2

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2003:818416 CAPLUS

DN 139:323436

TI Preparation of pyridinoylpiperidines as 5-HT1F agonists

IN Cohen, Michael Philip; Kohlman, Daniel Timothy; Liang, Sidney Xi; Mancuso, Vincent; Victor, Frantz; Xu, Yao-Chang; Ying, Bai-Ping; Zacherl, Deanna Piatt; Zhang, Deyi

PA Eli Lilly and Company, USA

SO PCT Int. Appl., 90 pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084949	A1	20031016	WO 2003-US8455	20030327
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	TW 263497	B	20061011	TW 2003-92106334	20030321
	NZ 534952	A	20051125	NZ 2003-534952	20030324
	CA 2478229	A1	20031016	CA 2003-2478229	20030327
	AU 2003224719	A1	20031020	AU 2003-224719	20030327
	EP 1492786	A1	20050105	EP 2003-721402	20030327
	EP 1492786	B1	20061004		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	BR 2003008495	A	20050201	BR 2003-8495	20030327
	CN 1642939	A	20050720	CN 2003-807363	20030327
	JP 2005530722	T	20051013	JP 2003-582146	20030327
	AT 341543	T	20061015	AT 2003-721402	20030327
	ZA 2004007666	A	20060222	ZA 2004-7666	20040922
	US 2005222206	A1	20051006	US 2004-509770	20040928
	NO 2004004654	A	20041028	NO 2004-4654	20041028
	HK 1073464	A1	20070504	HK 2005-104936	20050613
PRAI	US 2002-369088P	P	20020329		
	WO 2003-US8455	W	20030327		
OS	CASREACT 139:323436; MARPAT 139:323436				
GI					



AB Title compds. [I; R1 = (substituted) alkyl, cycloalkyl, cycloalkylalkyl, Ph, heterocycle; R2 = H, alkyl, cycloalkylalkyl, pyrazolylalkyl; R3 = H, alkyl; R4 = H, halo, alkyl; R5 = H, alkyl], were prepared for activating 5-HT1F receptors, inhibiting neuronal protein extravasation, and for the treatment or prevention of migraine. Thus, 2-amino-6-(1-methylpiperidin-4-ylcarbonyl)pyridine (preparation given), 4-fluorobenzoyl chloride, and Et3N were stirred in CH2Cl2 at room temperature for 4 h to give 4-fluoro-N-[6-(1-methylpiperidin-4-ylcarbonyl)pyridin-2-yl]benzamide dihydrochloride. I bound to as 5-HT1F receptors with Ki <300 nM. I drug formulations are given.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:218963 CAPLUS
DN 130:352171
TI Synthesis and antinociceptive activity of some 3-chlorophenyl- and 6-chloro-2-pyridinyl derivatives
AU Radl, Stanislav; Hafner, Wieland; Hezky, Petr; Krejci, Ivan; Proska, Jan; Hajicek, Josef
CS Research Institute of Pharmacy and Biochemistry, Prague, 13060/3, Czech Rep.
SO Collection of Czechoslovak Chemical Communications (1999), 64(2), 377-388
CODEN: CCCCAK; ISSN: 0010-0765
PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
DT Journal
LA English
AB Derivs. of 2-chloro-6-(4-hydroxy-1-methyl-4-piperidinyl)pyridine were prepared and tested as analgesics. 2-Chloro-6-lithiopyridine treated with 3-quinuclidinone, 1-methyl-3-pyrrolidinone, 2-(dimethylaminomethyl)cyclohexanone, and Et 1-methyl-4-piperidinylcarboxylate provided the corresponding alcs. A ketone was reduced with sodium borohydride or treated with methylmagnesium chloride or phenyllithium to provide the corresponding alcs. 1-[4-(6-Chloro-2-pyridyl)-1-methyl-4-piperidinyl]-1-methylethanol was prepared from 2-chloro-6-(1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)pyridine by treatment with butyllithium and acetone followed by reduction of an intermediate with sodium cyanoborohydride.

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 2

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2007 ACS on STN
AN 1999:218963 CAPLUS
DN 130:352171
TI Synthesis and antinociceptive activity of some 3-chlorophenyl- and 6-chloro-2-pyridinyl derivatives
AU Radl, Stanislav; Hafner, Wieland; Hezky, Petr; Krejci, Ivan; Proska, Jan; Hajicek, Josef
CS Research Institute of Pharmacy and Biochemistry, Prague, 13060/3, Czech Rep.
SO Collection of Czechoslovak Chemical Communications (1999), 64(2), 377-388
CODEN: CCCCAK; ISSN: 0010-0765
PB Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic
DT Journal
LA English
AB Derivs. of 2-chloro-6-(4-hydroxy-1-methyl-4-piperidinyl)pyridine were prepared and tested as analgesics. 2-Chloro-6-lithiopyridine treated with 3-quinuclidinone, 1-methyl-3-pyrrolidinone, 2-(dimethylaminomethyl)cyclohexanone, and Et 1-methyl-4-

piperidinylcarboxylate provided the corresponding alcs. A ketone was reduced with sodium borohydride or treated with methylmagnesium chloride or phenyllithium to provide the corresponding alcs. 1-[4-(6-Chloro-2-pyridyl)-1-methyl-4-piperidinyl]-1-methylethanol was prepared from 2-chloro-6-(1-methyl-1,2,5,6-tetrahydro-4-pyridinyl)pyridine by treatment with butyllithium and acetone followed by reduction of an intermediate with sodium cyanoborohydride.

IT 225112-39-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation and analgesic activity of (piperidinyl)pyridinemethanol or (pyridinyl)cyclohexanol or (pyridinyl)piperidinemethanol derivs.)


RN 225112-39-0 CAPLUS

CN 2-Pyridinemethanol, 6-chloro- α -(1-methyl-4-piperidinyl)- α -phenyl-, (2Z)-2-butenedioate (1:1) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 225112-26-5

CMF C18 H21 Cl N2 O




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.




IT 225112-16-3P 225112-26-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and analgesic activity of (piperidinyl)pyridinemethanol or (pyridinyl)cyclohexanol or (pyridinyl)piperidinemethanol derivs.)


RN 225112-16-3 CAPLUS

CN Methanone, (6-chloro-2-pyridinyl) (1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)



RN 225112-26-5 .CAPLUS

CN 2-Pyridinemethanol, 6-chloro- α -(1-methyl-4-piperidiny)- α -phenyl- (9CI) (CA INDEX NAME)



=> d his 123-124

(FILE 'CAPLUS' ENTERED AT 08:43:31 ON 30 MAY 2007)

L23 7 S L3

L24 5 S L3 NOT L6

=> d bib abs hitstr 1-5

L24 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2006:766432 CAPLUS

DN 145:195697

TI Compositions comprising a 5-HTiF-specific agonist and an NSADD and therapeutic methods for migraine and headache pain

IN Plachetka, John R.

PA Pozen Inc., USA

SO PCT Int. Appl., 35pp.


CODEN: PIXXD2

DT Patent


LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006081127	A2	20060803	WO 2006-US1882	20060119
	WO 2006081127	A3	20070308		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	US 2006178349	A1	20060810	US 2006-332795	20060117
PRAI	US 2005-645599P	P	20050124		
	US 2006-332795	A	20060117		
AB	The present invention is directed to compns. containing a 5-HTiF-specific agonist that acts by blocking protein extravasation together with an NSADD. These compns. may be used to treat migraine and headache pain. The invention also includes methods in which these drugs are sep. administered to a patient.				
IT	439239-90-4	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. comprising 5-HTiF-specific agonist and NSADD and therapeutic methods for migraine and headache pain)			
RN	439239-90-4	CAPLUS			
CN	Benzamide, 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)				



L24 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 2005:991014 CAPLUS
 DN 145:145570
 TI A novel method for the synthesis of carbon-14-labeled N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide and its use in quantitative whole-body autoradiography studies
 AU Wheeler, William J.; Chay, Sylvia H.; Herman, Jennifer L.; O'Bannon, Douglas D.
 CS Lilly Research Laboratories, A Division of Eli Lilly and Company, Indianapolis, IN, 46285, USA
 SO Journal of Labelled Compounds & Radiopharmaceuticals (2005), 48(9), 669-681
 CODEN: JLCRD4; ISSN: 0362-4803
 PB John Wiley & Sons Ltd.
 DT Journal
 LA English
 OS CASREACT 145:145570
 GI



AB Sumatriptan, a non-selective 5-HT_{1B/1D} agonist is an effective therapeutic agent for the acute treatment of migraine, but it is contraindicated for use in patients with known heart disease. The first Selective Serotonin One F Receptor Agonist (SSOFRA), 5-(4'-fluorobenzamido)-3-(N-methyl-piperidin-4-yl)-1H-indole was demonstrated to be clin. useful in the treatment of migraine. Although it exhibited high affinity for the 5-HT_{1F} receptor as well as high selectivity for the 5-HT_{1F} receptor relative to 5-HT_{1B} and 5-HT_{1D} receptors, it demonstrated appreciable affinity for the 5-HT_{1A} receptor. Subsequently, a program was launched to discover SSOFRA's with improved selectivity over other 5-HT₁ receptor subtypes. As a result of these efforts, N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]propanamide (I) was found to possess greater than 100-fold

selectivity over 5-HT1A, 5-HT1B and 5-HT1D receptors. Pursuant to a potential clin. investigation of I, its carbon-14-labeled isotopomer has been prepared by a circuitous route from unlabeled I and used in quant. whole-body autoradiog. studies in rats. The results of these efforts are reported herein.


IT 899827-19-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and pharmacokinetics of C14-labeled propanoylamino(methylpiperidinyl)pyrrolopyridine succinate via oxidative cleavage of acetylamino(methylpiperidinyl)indole followed by cyclization reduction, and addition of succinic acid)

RN 899827-19-1 CAPLUS

CN Propanamide, N-[5-(formylamino)-6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]- (9CI) (CA INDEX NAME)



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN

AN 2004:333695 CAPLUS

DN 140:339199

TI Preparation of 1,4-disubstituted piperidine derivatives and their use as 11-βHSD1 inhibitors

IN Barton, Peter John; Jewsbury, Philip John; Pease, Janet Elizabeth

PA Astrazeneca Ab, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 144 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004033427	A1	20040422	WO 2003-GB4318	20031007
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2501611	A1	20040422	CA 2003-2501611	20031007
AU 2003269242	A1	20040504	AU 2003-269242	20031007
EP 1556349	A1	20050727	EP 2003-751021	20031007
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003015166	A	20050816	BR 2003-15166	20031007
CN 1723199	A	20060118	CN 2003-80105353	20031007

JP 2006506451	T	20060223	JP 2005-500993	20031007
NO 2005001600	A	20050613	NO 2005-1600	20050330
US 2005256159	A1	20051117	US 2005-529951	20050401
ZA 2005002752	A	20060222	ZA 2005-2752	20050405
PRAI GB 2002-23573	A	20021011		
GB 2003-10446	A	20030507		
WO 2003-GB4318	W	20031007		
OS MARPAT 140:339199				
GI				



AB The title compds. [I; A = carbocyclyl, heterocyclyl; R1 = halo, NO2, CN, OH, etc.; n = 0-5; X = a bond, CO, SO2, CONR11, CSNR11, C(O)O, C(:NR11), CH2 (wherein R11 = H, alkyl, carbocyclyl, heterocyclyl); Y = H, alkyl, alkenyl, carbocyclyl, etc.; R12 = OH, Me, Et. Pr; m, q = 0-1], useful in the manufacture of a medicament for treating diabetes, obesity, hyperlipidemia, etc., were prepared. Thus, reacting (4-chlorophenyl)(4-piperidyl)methanone.HCl with 4-fluorobenzoyl chloride in the presence of Et3N in DCM afforded 29% 1-(4-fluorobenzoyl)-4-(4-chlorobenzoyl)piperidine. The compds. I typically show an IC50 < 10 μ M against 11 β HSD1. The pharmaceutical composition comprising the compound I is claimed.


IT 681133-44-8P 681134-40-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,4-disubstituted piperidine derivs. and their use as 11- β HSD1 inhibitors)


RN 681133-44-8 CAPLUS

CN Piperidine, 1-(4-fluorobenzoyl)-4-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RN 681134-40-7 CAPLUS



CN Piperidine, 1-[(4-fluorophenyl)sulfonyl]-4-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



RE.CNT 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
AN 2002:314934 CAPLUS
DN 136:340592
TI Preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine H3 receptors
IN Aslanian, Robert G.; Shih, Neng-Yang; Ting, Pauline C.; Berlin, Michael Y.; Rosenblum, Stuart B.; McCormick, Kevin D.; Tom, Wing C.; Boyce, Christopher W.; Mangiaracina, Pietro; Mutahi, Mwangi Wa; Piwinski, John J.
PA Schering Corporation, USA
SO PCT Int. Appl., 144 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002032893	A2	20020425	WO 2001-US32151	20011015
	WO 2002032893	A3	20020822		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KP, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2424664	A1	20020425	CA 2001-2424664	20011015
	AU 200215355	A	20020429	AU 2002-15355	20011015
	US 2003045519	A1	20030306	US 2001-978267	20011015
	US 6720328	B2	20040413		
	BR 2001014754	A	20030701	BR 2001-14754	20011015
	EP 1326858	A2	20030716	EP 2001-983968	20011015
	EP 1326858	B1	20051214		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CN 1469873	A	20040121	CN 2001-817512	20011015
	HU 200303835	A2	20040301	HU 2003-3835	20011015
	JP 2004511553	T	20040415	JP 2002-536275	20011015
	NZ 524857	A	20041224	NZ 2001-524857	20011015
	EP 1571145	A1	20050907	EP 2005-9405	20011015
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR				
	AT 312833	T	20051215	AT 2001-983968	20011015
	ES 2250500	T3	20060416	ES 2001-1983968	20011015
	CN 1803795	A	20060719	CN 2005-10131094	20011015
	TW 258474	B	20060721	TW 2001-90125385	20011015
	ZA 2003002521	A	20040630	ZA 2003-2521	20030331
	IN 2003CN00528	A	20050415	IN 2003-CN528	20030411
	NO 2003001744	A	20030614	NO 2003-1744	20030415
	HK 1052935	A1	20060519	HK 2003-105161	20030717
	US 2004097513	A1	20040520	US 2003-699189	20031031
	AU 2006252027	A1	20070111	AU 2006-252027	20061213
PRAI	US 2000-240901P	P	20001017		
	AU 2002-215355	A3	20011015		
	CN 2001-817512	A3	20011015		
	EP 2001-983968	A3	20011015		
	US 2001-978267	A3	20011015		
	WO 2001-US32151	W	20011015		
OS	MARPAT 136:340592				
GI					



AB The title compds. [I; R1 = (un)substituted aryl, heteroaryl, alkyl, etc.; X = CO, C(NOR3), C(NNR4R5), etc.; M1 = C; M2 = C, N; M3, M4 = C, N; Y = CH2, CO, C(NOH), etc.; Z = alkyl; R2 = (un)substituted 5-6 membered heteroaryl; R3 = H, alkyl, aryl, etc.; R4 = H, alkyl, aryl, etc.; R5 = H, alkyl, COR4, etc.; R12, R13 = alkyl, OH, alkoxy, F; a, b = 0-2; n, p = 1-3, with the proviso that when M3 and M4 are both N atoms, then p = 2 or 3], useful in treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion), were prepared E.g., a multi-step synthesis of II which showed Ki of 0.83 nM in H3 receptor binding assay, was given. Also disclosed are methods of treating various diseases or conditions, such as, for example, allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion) using the compds. I in combination with a H1 receptor antagonist.


IT 416850-86-7P 416851-23-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-[4-(piperidin-1-ylcarbonyl)piperidin-1-ylmethyl]pyridin-2-ylamines as antagonists of histamine H3 receptors)


RN 416850-86-7 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(6-methoxy-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)




RN 416851-23-5 CAPLUS

CN Piperidine, 1-[[1-[(2-amino-4-pyridinyl)methyl]-4-piperidinyl]carbonyl]-4-[(6-methyl-2-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)



L24 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2007 ACS on STN
 AN 1994:457281 CAPLUS
 DN 121:57281
 TI Dual antagonists of platelet activating factor and histamine. 2. Pyridine ring substitution of N-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines
 AU Wong, Jesse K.; Piwinski, John J.; Green, Michael J.; Ganguly, Ashit K.; Anthes, John C.; Billah, M. Motasim
 CS Dep. Chem. Res., Schering-Plough Res. Inst., Kenilworth, NJ, 07033-0539, USA
 SO Bioorganic & Medicinal Chemistry Letters (1993), 3(6), 1073-8
 CODEN: BMCLE8; ISSN: 0960-894X
 DT Journal
 LA English
 GI



I

AB A series of pyridine ring substituted 1-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines (I; X, Z = H, Me, OH, OMe; Y = H, Me, Cl, Ph, OMe, SMe, CHO, CH₂OH, Ac, Br), which are antagonists of both PAF and histamine, were prepared by one of three different methods. Analogs with substituents at C-3 were found to be the best dual antagonists among their corresponding regioisomers. Analogs with an electron donating substituent at the C-3 position are generally better antagonists of both PAF and histamine than analogs with electron withdrawing groups.
 IT 156073-04-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and reactions of, in synthesis of benzocycloheptapyridinylidene piperidines)
 RN 156073-04-0 CAPLUS
 CN Methanone, [3-[2-(3-chlorophenyl)ethyl]-6-methyl-2-pyridinyl] (1-methyl-4-piperidinyl)- (9CI) (CA INDEX NAME)

